CPRX Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
EN
06/10/2020

Underlying

CPRXCatalyst Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Catalyst Pharmaceuticals

 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results ...

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM E...

November 5, 2025 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to...

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be na...

November 4, 2025 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare...

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...

October 22, 2025 1 EN
 PRESS RELEASE
Free
CPRX Catalyst Pharma...

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch